Bevacizumab in the therapy for refractory metastatic colorectal cancer

References

• CassidyJCSDiaz-RubioEScheithauerWGrunbergSM2007XELOX vs. FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC)2007Gastrointestinal Cancers SymposiumOrlando FloridaAmerican Society of Clinical Oncology
   Google Scholar
• ChenHXMooneyMBoronM2006Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301J Clin Oncol2433546016849749
   PubMed Web of Science ®Google Scholar
• ColucciGGebbiaVPaolettiG2005Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia MeridionaleJ Clin Oncol2348667515939922
   PubMed Web of Science ®Google Scholar
• CunninghamDHumbletYSienaS2004Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerN Engl J Med3513374515269313
   PubMed Web of Science ®Google Scholar
• CunninghamDPyrhonenSJamesRD1998Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerLancet352141389807987
   PubMed Web of Science ®Google Scholar
• De GramontAFigerASeymourM2000Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerJ Clin Oncol1829384710944126
   PubMed Web of Science ®Google Scholar
• DouillardJYCunninghamDRothAD2000Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialLancet3551041710744089
   PubMed Web of Science ®Google Scholar
• EllisLMTakahashiYLiuW2000Vascular endothelial growth factor in human colon cancer: biology and therapeutic implicationsOncologist5Suppl 111510804085
   PubMedGoogle Scholar
• FerraraNDavis-SmythT1997The biology of vascular endothelial growth factorEndocr Rev184259034784
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJ2007Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol25153944
   Google Scholar
• GoldbergRMSargentDJMortonRF2004A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancerJ Clin Oncol22233014665611
   PubMed Web of Science ®Google Scholar
• GrotheyASargentDGoldbergRM2004Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatmentJ Clin Oncol2212091415051767
   PubMed Web of Science ®Google Scholar
• GrotheyASugrueMHedrickEThe Brite Study Investigators2007Association between exposure to bevacizumab (BV. beyond first progression (BBP. and overall survival (OS. in patients (pts. with metastatic colorectal cancer (mCRC.: Results from a large observational study (BRiTEJ Clin Oncol 2007 ASCO Annual Meeting Proceedings25
   Google Scholar
• HurwitzHFehrenbacherLNovotnyW2004Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med35023354215175435
   PubMed Web of Science ®Google Scholar
• HurwitzHIHoneycuttWHaleyS2006Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case reportClin Colorectal Cancer666916796794
   PubMed Web of Science ®Google Scholar
• InceWLJubbAMHoldenSN2005Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumabJ Natl Cancer Inst97981915998951
   PubMed Web of Science ®Google Scholar
• JainRK1994Barriers to drug delivery in solid tumorsSci Am27158658066425
   PubMed Web of Science ®Google Scholar
• JainRK2005Normalization of tumor vasculature: an emerging concept in antiangiogenic therapyScience307586215637262
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardE2007Cancer statistics, 2007CA Cancer J Clin57436617237035
   PubMed Web of Science ®Google Scholar
• JubbAMHurwitzHIBaiW2006Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancerJ Clin Oncol242172716365183
   PubMed Web of Science ®Google Scholar
• JubbAMPhamTQHanbyAM2004Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumoursJ Clin Pathol575041215113858
   PubMed Web of Science ®Google Scholar
• KabbinavarFFHambletonJMassRD2005aCombined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerJ Clin Oncol2337061215867200
   PubMed Web of Science ®Google Scholar
• KabbinavarFFSchulzJMcCleodM2005bAddition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trialJ Clin Oncol23369770515738537
   PubMed Web of Science ®Google Scholar
• KimKJLiBWinerJ1993Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature36284147683111
   PubMed Web of Science ®Google Scholar
• Maindrault-GoebelFDe GramontALouvetC2000Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX. in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR)Ann Oncol1114778311142489
   PubMed Web of Science ®Google Scholar
• Maindrault-GoebelFDe GramontALouvetC2001High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)Eur J Cancer371000511334725
   PubMed Web of Science ®Google Scholar
• Maindrault-GoebelFLledoGChibaudelBGERCOR2007Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR studyJ Clin Oncol, 2007 ASCO Annual Meeting Proceedings25
   Google Scholar
• ManleyPWMartiny-BaronGSchlaeppiJM2002Therapies directed at vascular endothelial growth factorExpert Opin Investig Drugs11171536
   PubMed Web of Science ®Google Scholar
• RothenbergMLOzaAMBigelowRH2003Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialJ Clin Oncol2120596912775730
   PubMed Web of Science ®Google Scholar
• RougierPVan CutsemEBajettaE1998Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerLancet3521407129807986
   PubMed Web of Science ®Google Scholar
• SaltzLBCoxJVBlankeC2000Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupN Engl J Med3439051411006366
   PubMed Web of Science ®Google Scholar
• SaltzLBDiaz-RubioEScheithauerWGrunbergSM2007Bevacizumab (Bev. in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC)2007 Gastrointestinal Cancers SymposiumOrlando FloridaAmerican Society of Clinical Oncology
   Google Scholar
• SaltzLBHochsterHWadlerS2005Randomized phase II Trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancerJ Clin Oncol, 2005 ASCO Annual Meeting Proceedings23
   Google Scholar
• TournigandCAndreTAchilleE2004FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyJ Clin Oncol222293714657227
   PubMed Web of Science ®Google Scholar
• TournigandCCervantesAFigerA2006OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR studyJ Clin Oncol2439440016421419
   PubMed Web of Science ®Google Scholar
• WillettCGBoucherYDi TomasoE2004Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerNat Med10145714745444
   PubMed Web of Science ®Google Scholar
• YangJCHaworthLSherryRM2003A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med3494273412890841
   PubMed Web of Science ®Google Scholar